|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:approvedBy
|
1953 (US)
|
|
gptkbp:ATCCode
|
P01BD01
|
|
gptkbp:bioavailability
|
90–100%
|
|
gptkbp:brand
|
gptkb:Daraprim
|
|
gptkbp:CASNumber
|
58-14-0
|
|
gptkbp:category
|
Antimalarial
Antiprotozoal
Dihydrofolate reductase inhibitor
|
|
gptkbp:combines
|
gptkb:Sulfadiazine
gptkb:Sulfonamides
|
|
gptkbp:contraindication
|
Megaloblastic anemia
|
|
gptkbp:costControversy
|
2015 price increase by Turing Pharmaceuticals
|
|
gptkbp:discoveredBy
|
gptkb:Gertrude_Elion
|
|
gptkbp:discoveredIn
|
1952
|
|
gptkbp:eliminationHalfLife
|
96 hours
|
|
gptkbp:excretion
|
Urine
|
|
gptkbp:foundIn
|
gptkb:WHO_Model_List_of_Essential_Medicines
|
|
gptkbp:hasMolecularFormula
|
C12H13ClN4
|
|
gptkbp:KEGGID
|
D00493
|
|
gptkbp:legalStatus
|
Prescription only
|
|
gptkbp:mechanismOfAction
|
Inhibits dihydrofolate reductase
|
|
gptkbp:meltingPoint
|
232–234 °C
|
|
gptkbp:metabolism
|
Liver
|
|
gptkbp:molecularWeight
|
248.71 g/mol
|
|
gptkbp:patentExpired
|
Yes
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
87%
|
|
gptkbp:PubChem_CID
|
4993
CHEMBL417
DB00205
|
|
gptkbp:routeOfAdministration
|
gptkb:Oral
|
|
gptkbp:sideEffect
|
gptkb:Nausea
Rash
Vomiting
Bone marrow suppression
|
|
gptkbp:synonym
|
2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine
|
|
gptkbp:UNII
|
362O9ITL9D
|
|
gptkbp:usedFor
|
Treatment of malaria
Treatment of toxoplasmosis
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
Yes
|
|
gptkbp:bfsParent
|
gptkb:Burroughs_Wellcome
|
|
gptkbp:bfsLayer
|
6
|
|
http://www.w3.org/2000/01/rdf-schema#label
|
Pyrimethamine
|